WuXi Biologics Recognized as Industry and Regional ESG Top-Rated Company by Morningstar Sustainalytics for Fifth Consecutive Year
WuXi Biologics (2269.HK) has been named a 2025 Industry and Regional ESG Top-Rated Company by Morningstar Sustainalytics for the fifth consecutive year, ranking in the top 1% of pharmaceutical companies assessed. This recognition comes from Sustainalytics' evaluation of over 15,000 companies across 42 industries worldwide.
The company has achieved several notable ESG milestones, including:
- Inclusion in the UNGC 20 Case Examples of Sustainable Development
- MSCI AAA Rating and inclusion in Dow Jones Sustainability Indices
- EcoVadis Platinum Medal
- CDP Water Security 'A list' and 'A-' Climate Change score
- Selection as FTSE4Good Index Series Constituent
- Listing in Hang Seng ESG 50 Index
As a global Contract Research, Development and Manufacturing Organization (CRDMO), WuXi Biologics operates with over 12,000 employees across China, the United States, Ireland, Germany and Singapore, supporting 817 integrated client projects, including 21 in commercial manufacturing.
WuXi Biologics (2269.HK) è stata nominata come una delle Aziende ESG di Settore e Regionali Top-Rated per il 2025 da Morningstar Sustainalytics per il quinto anno consecutivo, classificandosi nel top 1% delle aziende farmaceutiche valutate. Questo riconoscimento deriva dalla valutazione di Sustainalytics di oltre 15.000 aziende in 42 settori a livello mondiale.
La società ha raggiunto diversi traguardi significativi in termini di ESG, tra cui:
- Inclusione negli Esempi di Caso di Sviluppo Sostenibile del UNGC 20
- Rating MSCI AAA e inclusione negli Indici di Sostenibilità di Dow Jones
- Medaglia Platino di EcoVadis
- Elenco 'A' di Sicurezza Idrica del CDP e punteggio 'A-' per il Cambiamento Climatico
- Selezione come Costituente della FTSE4Good Index Series
- Inclusione nell'Hang Seng ESG 50 Index
In qualità di Organizzazione Globale di Ricerca, Sviluppo e Produzione a Contratto (CRDMO), WuXi Biologics opera con oltre 12.000 dipendenti in Cina, Stati Uniti, Irlanda, Germania e Singapore, supportando 817 progetti integrati per i clienti, di cui 21 nella produzione commerciale.
WuXi Biologics (2269.HK) ha sido nombrada como una de las Empresas ESG de Industria y Regionales Mejor Calificadas para 2025 por Morningstar Sustainalytics por quinto año consecutivo, clasificándose en el top 1% de las empresas farmacéuticas evaluadas. Este reconocimiento proviene de la evaluación de Sustainalytics de más de 15,000 empresas en 42 industrias a nivel mundial.
La compañía ha logrado varios hitos notables en ESG, incluyendo:
- Inclusión en los Ejemplos de Casos de Desarrollo Sostenible del UNGC 20
- Calificación MSCI AAA e inclusión en los Índices de Sostenibilidad de Dow Jones
- Medalla de Platino de EcoVadis
- Lista 'A' de Seguridad del Agua del CDP y puntuación 'A-' por Cambio Climático
- Selección como Constituyente de la Serie FTSE4Good Index
- Listado en el Índice ESG 50 de Hang Seng
Como una Organización Global de Investigación, Desarrollo y Fabricación por Contrato (CRDMO), WuXi Biologics opera con más de 12,000 empleados en China, Estados Unidos, Irlanda, Alemania y Singapur, apoyando 817 proyectos integrados para clientes, de los cuales 21 en fabricación comercial.
우시 생명과학 (2269.HK)는 모닝스타 서스테이널리틱스로부터 2025년 산업 및 지역 ESG 최고 평가 기업으로 선정되었으며, 이는 5년 연속으로 이루어진 일입니다. 이는 평가된 제약 회사 중 상위 1%에 해당합니다. 이 인식은 서스테이널리틱스가 전 세계 42개 산업에서 15,000개 이상의 회사에 대한 평가를 통해 이루어진 것입니다.
이 회사는 다음과 같은 여러 주목할 만한 ESG 이정표를 달성했습니다:
- UNGC 20 사례의 지속 가능한 발전 예시 포함
- MSCI AAA 등급 및 다우존스 지속 가능성 지수 포함
- EcoVadis 플래티넘 메달
- CDP 물 안전 'A 리스트' 및 'A-' 기후 변화 점수
- FTSE4Good 인덱스 시리즈 구성원 선정
- 항셍 ESG 50 인덱스 상장
글로벌 계약 연구, 개발 및 제조 조직(CRDMO)으로서 우시 생명과학은 중국, 미국, 아일랜드, 독일 및 싱가포르에 걸쳐 12,000명 이상의 직원을 두고 있으며, 상업 제조를 포함하여 817개의 통합 고객 프로젝트를 지원하고 있습니다.
WuXi Biologics (2269.HK) a été nommé comme une entreprise classée parmi les meilleures en matière d'ESG pour l'industrie et la région pour 2025 par Morningstar Sustainalytics pour la cinquième année consécutive, se classant dans le top 1% des entreprises pharmaceutiques évaluées. Cette reconnaissance provient de l'évaluation de Sustainalytics de plus de 15 000 entreprises dans 42 secteurs à travers le monde.
L'entreprise a atteint plusieurs jalons ESG notables, notamment:
- Inclusion dans les Exemples de Cas de Développement Durable des 20 de l'UNGC
- Note MSCI AAA et inclusion dans les indices de durabilité Dow Jones
- Médaille Platine d'EcoVadis
- Liste 'A' de Sécurité de l'Eau et score 'A-' pour le Changement Climatique de CDP
- Sélection en tant que Constituant de la Série FTSE4Good Index
- Inscription dans l'Indice ESG 50 de Hang Seng
En tant qu'Organisation Mondiale de Recherche, Développement et Fabrication sous Contrat (CRDMO), WuXi Biologics emploie plus de 12 000 personnes en Chine, aux États-Unis, en Irlande, en Allemagne et à Singapour, soutenant 817 projets intégrés pour les clients, dont 21 dans la fabrication commerciale.
WuXi Biologics (2269.HK) wurde für das Jahr 2025 von Morningstar Sustainalytics zum fünften Mal in Folge als eines der besten ESG-Unternehmen der Branche und der Region ausgezeichnet und gehört damit zu den besten 1% der bewerteten Pharmaunternehmen. Diese Anerkennung resultiert aus der Bewertung von Sustainalytics von über 15.000 Unternehmen aus 42 Branchen weltweit.
Das Unternehmen hat mehrere bemerkenswerte ESG-Meilensteine erreicht, darunter:
- Einbeziehung in die UNGC 20 Fallbeispiele für nachhaltige Entwicklung
- MSCI AAA-Bewertung und Aufnahme in die Dow Jones Nachhaltigkeitsindizes
- EcoVadis Platinmedaille
- CDP Wassersicherheits-'A-Liste' und 'A-' Klimawandel-Score
- Auswahl als Bestandteil der FTSE4Good-Indexserie
- Listung im Hang Seng ESG 50 Index
Als globale Vertragsforschungs-, Entwicklungs- und Herstellungsorganisation (CRDMO) beschäftigt WuXi Biologics über 12.000 Mitarbeiter in China, den Vereinigten Staaten, Irland, Deutschland und Singapur und unterstützt 817 integrierte Kundenprojekte, darunter 21 in der kommerziellen Produktion.
- None.
- None.
- Ranked among the top
1% of companies assessed in the pharmaceutical industry - Recognized as a leader in Green CRDMO, driving innovation for a healthier future
- Committed to creating long-term value for all stakeholders
Sustainalytics, a leading ESG data, research, and ratings firm, supports global investors with the development and implementation of responsible investment strategies. Its 2025 ESG Risk Ratings cover more than 15,000 companies across 42 industries worldwide, with Top-Rated Badges given to those companies with the strongest ESG achievements. WuXi Biologics ranks in the top
Dr. Chris Chen, CEO of WuXi Biologics and Chairman of its ESG Committee, commented, "We are very pleased to once again receive this honor from Morningstar Sustainalytics. It is a reflection and recognition of our ongoing commitment to enhancing sustainability capabilities. As a global leader in Green CRDMO, we consistently deliver our own ESG excellence while enabling partners worldwide to fulfill their ESG commitments, jointly working with all stakeholders to promote responsible practices throughout the entire value chain."
In recent years, WuXi Biologics' ESG strategy and initiatives have made significant progress and gained widespread recognition. The Company was included in the UNGC 20 Case Examples of Sustainable Development for 20 Years Collection for its world-leading green biologics solutions; granted an MSCI AAA Rating and included in Dow Jones Sustainability Indices for two consecutive years; awarded the distinguished Platinum Medal by EcoVadis; named to the CDP Water Security "A list" and awarded an "A-" CDP Climate Change score; selected as a Constituent of FTSE4Good Index Series; and listed in the Hang Seng ESG 50 Index.
About Morningstar Sustainalytics
Morningstar Sustainalytics is a leading independent ESG and corporate governance research, ratings and analytics firm that supports investors around the world with the development and implementation of responsible investment strategies. For more than 30 years, the firm has been at the forefront of developing high-quality, innovative solutions to meet the evolving needs of global investors.
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
With over 12,000 skilled employees in
WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to be an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.
For more information about WuXi Biologics, please visit: www.wuxibiologics.com.
View original content:https://www.prnewswire.com/news-releases/wuxi-biologics-recognized-as-industry-and-regional-esg-top-rated-company-by-morningstar-sustainalytics-for-fifth-consecutive-year-302372189.html
SOURCE WuXi Biologics
FAQ
What ESG rating did WuXi Biologics (2269.HK) receive from Sustainalytics in 2025?
How many consecutive years has WuXi Biologics (2269.HK) maintained top ESG ratings?
How many integrated client projects is WuXi Biologics (2269.HK) supporting as of December 2024?
What major ESG recognitions has WuXi Biologics (2269.HK) received besides Sustainalytics?
How many employees does WuXi Biologics (2269.HK) have globally?
